We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.95B
1-Year Est. Return
773.9%
This Fund
S&P 500
This Quarter
Est. Return
+19.76%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$1.95B
AUM Growth
-$39.6M
(-2%)
Cap. Flow
-$245M
Cap. Flow
% of AUM
-12.56%
Top 10 Holdings %
Top 10 Hldgs %
59.19%
Holding
59
New
12
Increased
4
Reduced
29
Closed
9
Avg Time Held Equity + Options
6
quarters
Top 10 Avg Time Held Equity + Options
2.5
quarters
Top 20 Avg Time Held Equity + Options
3.9
quarters
Avg Time Held Equity only
6
quarters
Top 10 Avg Time Held Equity only
3.3
quarters
Top 20 Avg Time Held Equity only
4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$128M |
| 2 |
Climb Bio
CLYM
|
+$21.8M |
| 3 |
Faeth Therapeutics
FTH
|
+$16.7M |
| 4 |
Spyre Therapeutics
SYRE
|
+$16.4M |
| 5 |
Adlai Nortye Group ADS
ANL
|
+$13.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Praxis Precision Medicines
PRAX
|
+$77.7M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$41.7M |
| 3 |
Edgewise Therapeutics
EWTX
|
+$25.9M |
| 4 |
Olema Pharmaceuticals
OLMA
|
+$23.4M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
+$23.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.09% |
| 2 | Financials | 0.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Spyre Therapeutics
SYRE
$8.03B
| $20M | 1.02% |
+225,000
| New | +$16.4M |
2026 Q2
0 quarters
|
|
27
Definium Therapeutics
DFTX
$4.73B
| $18.8M | 0.96% |
+400,000
| New | +$9.88M |
2026 Q2
0 quarters
|
|
28
NewAmsterdam Pharma
NAMS
$2.54B
| $16.9M | 0.87% |
500,000
-450,000
| -47% | -$14.8M |
2024 Q1
9 quarters
|
|
29
Roivant Sciences
ROIV
$25B
| $16.8M | 0.86% |
475,000
-275,000
| -37% | -$8.13M |
2026 Q1
1 quarter
|
|
30
Cabaletta Bio
CABA
$303M
| $15.6M | 0.8% |
5,000,000
-500,000
| -9% | -$1.64M |
2025 Q2
4 quarters
|
|
31
Helix Acquisition Corp III
HLXC
$232M
| $13.8M | 0.71% |
1,297,500
| – | – |
2026 Q1
1 quarter
|
|
32
Ascendis Pharma A/S
ASND
$14.9B
| $13.3M | 0.68% |
50,000
-45,000
| -47% | -$10.5M |
2025 Q4
2 quarters
|
|
33
Kailera Therapeutics
KLRA
$1.47B
| $12.1M | 0.62% |
+550,000
| New | +$12.1M |
2026 Q2
0 quarters
|
|
34
Insmed
INSM
$21.5B
| $8M | 0.41% |
75,000
-115,000
| -61% | -$13.9M |
2023 Q3
11 quarters
|
|
|
35
Faeth Therapeutics
FTH
$601M
| $7.66M | 0.39% |
1,028,242
+722,020
| +236% | +$16.7M |
2026 Q1
1 quarter
|
|
36
Enliven Therapeutics
ELVN
$2.99B
| $7.61M | 0.39% |
+150,000
| New | +$6.37M |
2026 Q2
0 quarters
|
|
37
Tarsus Pharmaceuticals
TARS
$3.48B
| $6.29M | 0.32% |
100,000
-125,000
| -56% | -$7.99M |
2020 Q4
22 quarters
|
|
38
iBio
IBIO
$58.1M
| $6.25M | 0.32% |
+3,570,000
| New | +$6.38M |
2026 Q2
0 quarters
|
|
39
DELISTED
Crinetics Pharmaceuticals
CRNX
| $4.68M | 0.24% |
125,000
-125,000
| -50% | -$4.65M |
2023 Q3
11 quarters
|
|
40
Arcutis Biotherapeutics
ARQT
$3.3B
| $4.59M | 0.24% |
175,000
-275,000
| -61% | -$6.41M |
2024 Q1
9 quarters
|
|
41
Arrowhead Research
ARWR
$8.58B
| $4.08M | 0.21% |
50,000
-50,000
| -50% | -$3.69M |
2026 Q1
1 quarter
|
|
42
Structure Therapeutics
GPCR
$1.71B
| $4.03M | 0.21% |
75,000
-100,000
| -57% | -$4.42M |
2026 Q1
1 quarter
|
|
43
Research Alliance Corp III
RACC
$92.6M
| $3.96M | 0.2% |
+370,000
| New | +$3.86M |
2026 Q2
0 quarters
|
|
44
Cogent Biosciences
COGT
$5.17B
| $3.87M | 0.2% |
100,000
-100,000
| -50% | -$3.5M |
2025 Q4
2 quarters
|
|
45
Altimmune
ALT
$498M
| $3.8M | 0.19% |
+1,250,000
| New | +$3.73M |
2026 Q2
0 quarters
|
|
46
Amylyx Pharmaceuticals
AMLX
$3.45B
| $3.59M | 0.18% |
200,000
-150,000
| -43% | -$2.32M |
2025 Q3
3 quarters
|
|
47
Odyssey Therapeutics
ODTX
$878M
| $3.27M | 0.17% |
+175,000
| New | +$3.07M |
2026 Q2
0 quarters
|
|
48
Vaxcyte
PCVX
$11B
| $2.91M | 0.15% |
50,000
-50,000
| -50% | -$2.72M |
2022 Q4
14 quarters
|
|
49
Boundless Bio
BOLD
$58.9M
| $2.5M | 0.13% |
+1,000,000
| New | +$1.54M |
2026 Q2
0 quarters
|
|
|
IRLA
50
IRulya Therapeutics Inc. Common Stock
IRLA
$33M
| $100K | 0.01% |
+5,498
| New | +$126K |
2026 Q2
0 quarters
|
|
Similar funds
AHC
FFS
GIP
SLF
BFPW
MSA
MAM
GF
Cormorant Asset Management's Q2 2026 Portfolio in Review
As of Q2 2026, Cormorant Asset Management held 59 positions worth $1.95B, down 2% from $1.99B the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Cormorant Asset Management withdrew a net $245M in Q2 2026, closing 9 positions and reducing 29 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $41.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.
Against the trend, Cormorant Asset Management opened a new position in Parabilis Medicines Inc worth $126M.
- Cormorant Asset Management's largest Q2 2026 buy was Parabilis Medicines Inc: 4,615,612 shares worth $126M.
- Cormorant Asset Management added most to Faeth Therapeutics in Q2 2026, an estimated $16.7M increase.
- Cormorant Asset Management's biggest Q2 2026 reduction was Praxis Precision Medicines, cutting an estimated $77.7M.
- Cormorant Asset Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.7M.
- Cormorant Asset Management's ten largest holdings make up 59% of its $1.95B portfolio in Q2 2026.
- Cormorant Asset Management opened 12 new positions and closed 9 in Q2 2026.
- Cormorant Asset Management's portfolio value fell 2% quarter-over-quarter to $1.95B.
Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.